Arena Pharmaceuticals EPS Ratio 2011-2026 | ARNA

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Arena Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-10.1	-7.39	7.99	1.39	-2.77	-0.09	-0.45	-0.28	-0.09	-0.45	-0.8

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
7.99	-10.1	-1.19

Quarterly EPS Ratio Arena Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-3.21	-2.4	-1.98	-2.1	-1.69	-1.61	-2	-1.76	-1.46	-1.24	12.5	1.39	-0.7	-0.65	-0.8	-0.35	-0.86	-0.77	-0.09	1.59	-0.51	-1.12	-0.89	-0.13	-0.11	-0.11	-0.1	-0.15	-0.05	0.03	-0.12	-0.11	-0.08	0.18	-0.09	-0.1	-0.07	-0.12	-0.18	-0.16	-0.16	-0.16	-0.35

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
12.5	-3.21	-0.298

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
AbbVie ABBV	1.02	$ 232.08	3.29 %	$ 411 B	USA
AbCellera Biologics ABCL	-0.49	$ 3.61	0.56 %	$ 1.08 B	Canada
Abeona Therapeutics ABEO	-2.53	$ 5.12	-1.54 %	$ 109 M	USA
Arbutus Biopharma Corporation ABUS	-0.44	$ 4.66	-0.85 %	$ 773 M	Canada
ACADIA Pharmaceuticals ACAD	1.37	$ 24.56	-0.32 %	$ 4.07 B	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Achieve Life Sciences ACHV	-1.5	$ 4.56	-3.59 %	$ 90.4 M	USA
AC Immune SA ACIU	-0.97	$ 2.93	-1.01 %	$ 229 M	Schweiz
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Aclaris Therapeutics ACRS	-0.53	$ 2.87	-8.31 %	$ 352 M	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Adagene ADAG	-0.59	$ 2.96	-4.67 %	$ 167 M	China
ADC Therapeutics SA ADCT	-3.77	$ 4.1	-0.73 %	$ 105 M	Schweiz
Adial Pharmaceuticals ADIL	-2.72	$ 2.53	-	$ 16.4 M	USA
ADMA Biologics ADMA	0.62	$ 15.57	2.57 %	$ 3.71 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Adaptive Biotechnologies Corporation ADPT	-0.39	$ 16.02	-2.67 %	$ 2.43 B	USA
ADiTx Therapeutics ADTX	-3.06 K	$ 0.46	-4.63 %	$ 6.06 K	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Agenus AGEN	-0.69	$ 3.33	-0.89 %	$ 1.19 M	USA
Agios Pharmaceuticals AGIO	-7.12	$ 30.23	0.83 %	$ 1.75 B	USA
AIM ImmunoTech AIM	-0.4	$ 0.91	-8.59 %	$ 43.8 M	USA
Akebia Therapeutics AKBA	-0.02	$ 1.31	-0.76 %	$ 337 M	USA
Akari Therapeutics, Plc AKTX	-0.09	$ 0.24	-8.87 %	$ 5.73 B	Britain
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Aldeyra Therapeutics ALDX	-0.56	$ 5.46	-0.73 %	$ 328 M	USA
Alector ALEC	-1.39	$ 2.43	-5.08 %	$ 250 M	USA
Aligos Therapeutics ALGS	-1.36	$ 7.03	-6.27 %	$ 452 M	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Alkermes plc ALKS	1.47	$ 30.1	-2.05 %	$ 4.96 B	Irlanda
Allogene Therapeutics ALLO	-2.09	$ 2.78	1.83 %	$ 436 M	USA
AIkido Pharma AIKI	-2.38	-	1.93 %	$ 17.4 M	USA
Alnylam Pharmaceuticals ALNY	2.39	$ 332.92	0.51 %	$ 43.6 B	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Altimmune ALT	-1.34	$ 4.31	-3.36 %	$ 306 M	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
ALX Oncology Holdings ALXO	-2.58	$ 2.11	-10.21 %	$ 110 M	USA
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
Amgen AMGN	14.3	$ 388.16	2.33 %	$ 209 B	USA
Aileron Therapeutics ALRN	-3.51	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA